Research programme: Herpes simplex virus helicase inhibitors - Boehringer Ingelheim
Latest Information Update: 24 Sep 2012
At a glance
- Originator Boehringer Ingelheim
- Class
- Mechanism of Action DNA helicase-primase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Herpes simplex virus infections
Most Recent Events
- 18 Sep 2012 Discontinued - Preclinical for Herpes simplex virus infections in Canada (PO)
- 20 Sep 2006 No development reported - Preclinical for Herpes simplex virus infections in Canada (PO)
- 03 Jul 2003 Preclinical trials in Herpes simplex virus infections in Canada (PO)